Bullish
Eli Lilly's Q2 2026 revenue surges 48%, raising full-year guidance to $85–87 billion.
Eli Lilly reported a 48% increase in Q2 2026 revenue, driven by strong sales of Mounjaro and Zepbound. The company raised its full-year revenue guidance to $85–87 billion, up from the previous estimate of $82.5–84.5 billion. Additionally, Lilly secured a licensing agreement with OmniAb valued at up to $370 million in milestone payments.
Key points
- Q2 2026 revenue increased by 48% to $23.0 billion, led by Mounjaro and Zepbound sales.
- Full-year revenue guidance raised to $85–87 billion, up from $82.5–84.5 billion.
- OmniAb licensing agreement could yield up to $370 million in milestone payments.
Sources
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressPR Newswire · August 5, 2026
- OmniAb en hausse grâce à un accord de recherche pharmaceutique avec Lilly d'une valeur pouvant atteindre 370 millions de dollarsBoursorama · August 17, 2026
AI-generated from public news sources. Not financial advice.
